Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.

Mary S AnthonyVanita R ArodaLauren E ParlettLeila DjebarriSofia BerreghisBrian CalingaertDaniel C BeachlerChristopher L CroweCatherine B JohannesJuhaeri JuhaeriStephan LanesChunshen PanKenneth J RothmanCatherine W SaltusKathleen E Walsh

Published in: Diabetes care (2024)

Anaphylaxis is rare with GLP-1 RAs. Lixisenatide is unlikely to confer higher risk of anaphylaxis than other GLP-1 RAs.

Keyphrases

wild type